CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
March 03 2015 - 08:15AM
Business Wire
Enrolls 25 patients during the month of
February
CEL-SCI Corporation (NYSE MKT: CVM) today announced that
in February it has enrolled 25 patients with advanced primary, not
yet treated, head and neck cancer into its global pivotal Phase III
head and neck cancer trial for its investigational immunotherapy
Multikine* (Leukocyte Interleukin, Injection). This follows
January’s prior record. A total of 377 patients have been enrolled
in the world’s largest Phase III study in head and neck cancer as
of February 28, 2015.
“We are pleased to have achieved this consecutive month of
record enrollment in 2015, particularly in light of the fact that
February was a shorter month. During the month of February we also
had a record number of patient screenings. During the month of
February we also received clearance in the Philippines, Malaysia
and Belarus to begin patient enrollment in those countries. This is
expected to result in an even higher number of patients being
enrolled in the study in March,” stated CEL-SCI Chief Executive
Officer Geert Kersten.
The goal is to enroll a total of 880 patients through
approximately 100 clinical centers in about 25 countries by the end
of 2015.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with
advanced primary, not yet treated, head and neck cancer. The
objective of the study is to demonstrate a statistically
significant improvement in the overall survival of enrolled
patients who are treated with the Multikine treatment regimen plus
Standard of Care (SOC) vs. subjects who are treated with SOC
only.
About Multikine
Multikine (Leukocyte Interleukin, Injection) is an
investigational immunotherapeutic agent that is being tested in an
open-label, randomized, controlled, global pivotal Phase III
clinical trial as a potential first-line treatment for advanced
primary head and neck cancer. If approved for use following
completion of CEL-SCI's clinical development program for head and
neck cancer, Multikine would be a different type of therapy in the
fight against cancer; one that appears to have the potential to
work with the body's natural immune system in the fight against
tumors. CEL-SCI is aiming to complete enrollment of subjects to the
Phase III head and neck cancer study by the end of 2015. The trial
is expected to expand into a total of approximately 100 clinical
centers in about 25 countries.
In October 2013, CEL-SCI announced that it had signed a CRADA
(Cooperative Research and Development Agreement) with the US Naval
Medical Center, San Diego, to develop Multikine as a potential
treatment for HIV/HPV co-infected men and women with peri-anal
warts. CEL-SCI also announced that it entered into two new
co-development agreements with Ergomed to further clinically
develop Multikine for cervical dysplasia/neoplasia in women who are
co-infected with HIV and HPV and for peri-anal warts in men and
women who are co-infected with HIV and HPV.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. CEL-SCI
believes that the best way may be to activate the immune system of
patients before they have received surgery, radiation and/or
chemotherapy. Its lead investigational therapy Multikine (Leukocyte
Interleukin, Injection) is currently being studied in a pivotal
Phase III clinical trial against head and neck cancer. If the study
endpoint, which is a 10% improvement in overall survival of the
subjects treated with Multikine treatment regimen as compared to
subjects treated with current standard of care only is satisfied,
the study results will be used to support applications which will
be submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
* Multikine is the trademark that CEL-SCI has registered for
this investigational therapy, and this proprietary name is subject
to FDA review in connection with our future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved for sale, barter or exchange by the FDA or any other
regulatory agency. Similarly, its safety or efficacy has not been
established for any use. Moreover, no definitive conclusions can be
drawn from the early-phase, clinical-trials data involving the
investigational therapy Multikine (Leukocyte Interleukin,
Injection). Further research is required, and early-phase clinical
trial results must be confirmed in the well-controlled, Phase III
clinical trial of this investigational therapy that is currently in
progress.
When used in this report, the words "intends," "believes,"
"anticipated", "plans" and "expects" and similar expressions are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC
filings, including but not limited to its report on Form 10-K for
the year ended September 30, 2014. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2023 to Mar 2024